New York, NY -- June 12, 2019 -- InvestorsHub NewsWire -- via NextBigTicker.com
GD Entertainment And Technology (GDET), Kali, Inc. (KALY) and Generex Biotechnology Corporation (GNBT) are all enjoying an uplift from the growing momentum within the CBD sector. All three have a unique CBD initiative to which the market is reacting positively. Both GDET and KALY are rated BULLISH and GNBT has a BUY recommendation.
GDET has recently launched a line of wellness and beauty CBD products that are selling well. The combine combines online sales with periodic Pop UP Shops. The PPS has recently dipped below $0.01. With the BULLISH rating and the prevailing CBD market, it looks like a good time to get in for a double, triple or more.
KALY has just signed a $5 million CBD extraction contract and introduced an all new extraction business line that KALY management believes can deliver $20 million in 2019 sales.
GNBT - GENEREX
GNBT is an old school pharmaceutical development company that has recently added a managed service organization (MSO) strategy to enhance their pharmaceutical development strategy in addition to entering into an agreement with a cannabis cultivator/extractor initiative to explore the development of cannabis therapies. Notably, the company has a NASDAQ listing initiative. This is a $1.50 stock that could go to $10.00 when the market releases the value of their drug development portfolio enhanced by the MSO strategy with the CBD sweetener.
NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.